NCT07517198 2026-04-08
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
Phase 1 Recruiting
Exscientia AI Limited
Roswell Park Cancer Institute
University Health Network, Toronto
Celldex Therapeutics